Table 3.
Supportive care agents by drug class administered within 5 days of onset of decreased appetite and outcomes of patients after intervention.
| No supportive care | Megestrol acetate | Cannabinoid receptor agonist | Glucocorticoid receptor agonist | Mirtazapine or olanzapine | |
|---|---|---|---|---|---|
| N (%) of patients with any grade decreased appetite | 197 (53%) | 22 (10%) | 13 (6%) | 26 (11%) | 12 (5%) |
| Grade 1 N (%) | 87 (44%) | 6 (27%) | 3 (23%) | 10 (39%) | 4 (33%) |
| Grade 2 N (%) | 96 (49%) | 15 (68%) | 10 (77%) | 11 (42%) | 7 (58%) |
| Grade 3 N (%) | 14 (7%) | 1 (5%) | – | 5 (19%) | 1 (8%) |
| AEs resolved/resolving N (%) | 87 (44%) | 14 (64%) | 10 (77%) | 8 (31%) | 6 (50%) |
| AEs not resolved/resolving N (%) | 110 (56%) | 8 (36%) | 3 (23%) | 18 (69%) | 6 (50%) |
| Median duration of event for resolved decreased appetite (days; Q1, Q3) | 36 (15, 109) | 21 (8, 29) | 41 (19, 54) | 14 (3, 33) | 8 (6, 25) |
Incidence and severity of decreased appetite at the time of supportive care with outcomes of patients who had intervention within 5 days of AE onset. Supportive care agents per drug class: cannabinoid receptor agonist (dronabinol, nabilone, cannabis sativa, glucocorticoid receptor (GR) agonist (dexamethasone, prednisolone, prednisone).